(Reuters) - French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus. The lawsuit, filed in United States District Court for the District of Delaware, was triggered by notification from Lilly last month that it applied with the U.S. Food and Drug Administration (FDA) seeking permission to sell a generic version of Lantus, known chemically as insulin glargine. Lilly, in its submission, challenged the validity of several patents on Lantus held by Sanofi. Indianapolis-based Lilly had said it will not launch its generic product before the February 2015 expiration of Sanofi's patent on the active ingredient in Lantus.
via Health News Headlines - Yahoo News http://ift.tt/1baYodm
No comments:
Post a Comment